- active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
United States · Australia · Belgium - authorisedPhase I and Phase II (Integrated)- Other
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
This study looks at a new medicine, Ifinatamab Deruxtecan, for children aged 1 month to under 12 years with certain cancers that haven't responded to other treatments. It aims to see how safe it is and if it helps shrink tumors or stop them from growing.
France · Spain · Sweden - recruitingPHASE2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
This study is looking into a new medicine, calderasib, to treat certain advanced cancers. Researchers want to see if it can shrink these cancers, either alone or with another medicine called cetuximab, in people whose cancers have a specific genetic change (KRAS G12C mutation).
United States · Australia · Canada - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
This study is testing a new medicine, INCA32459, for people with certain advanced cancers like melanoma or lymphoma. It's an early-stage study to see how the medicine works and if it's safe.
Belgium · Spain · Italy - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)
This study is looking at a new combination of medicines for some types of cancer, called MK-4280A and pembrolizumab. It wants to see how well these medicines shrink tumours and if they help people feel better. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
France · Italy · Netherlands